https://www.selleckchem.com/pr....oducts/tolebrutinib-
An unadjusted repeated measures model was used in the analysis with statistical significance set at p ≤ 0.05. RESULTS Our cohort prevalence of CD was 3.9% (2 M 9 F, mean age 49.8 yrs.). Within both the Gp + CD Gp subgroups, UGI Sx substantially improved after temporary and permanent GES. Furthermore, 55% of the GP + CD subgroup demonstrated a clinical response by HBI, while one patient achieved clinical remission (p less then 0.01). CD medications were reviewed before and after GES placement, and any interva
Like
Comment
Share
